首页 CASI制药(usCASI)-基本信息

CASI制药(usCASI)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:CASI制药


英文名称:CASI Pharmaceuticals


简介:CASI制药公司是一家临床阶段的制药公司,主要开发用于治疗癌症和炎症疾病的新一代多机制药物


电话:1-240-8642600


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

CASI是一家生物制药公司,专注于优质药品的收购,开发和商业化以及针对全球市场解决癌症和其他未满足医疗需求的创新疗法,重点关注大中华地区和美国。公司是纳斯达克上市公司,总部位于马里兰州罗克维尔,在中国北京设有全资子公司和研发中心。CASI制药的使命是成为一家在中国拥有巨大市场份额的综合性生物制药公司,同时建立全球发展和商业化的合作伙伴关系。公司的战略的一部分是利用其在中国和美国的专业知识和资源,为患者提供高质量的药品和创新的抗肿瘤产品,并利用其中国 - 美国双重身份,更具成本效益地开发药物。CASI的产品组合包括:1)Spectrum Pharmaceuticals, Inc.旗下经FDA批准上市的药物,由公司授权许可在中国地区销售的:注射用EVOMELA®(美法仑)、MARQIBO®,(vinCRIStine硫酸盐LIPOSOME注射液)、ZEVALIN®(ibritumomab tiuxetan)2)ENMD-2076( II 期临床阶段)3)用于治疗乙型肝的炎恩替卡韦(entecavir)和其他美国ANDA产品4)CASI-001和CASI-002,专有的免疫肿瘤学临床前候选药物。

交易日期 交易人 职位 类型 交易份额 价格
2016-10-27 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 773790 0.01
2016-10-27 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 521692 0.01
2016-10-27 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 294815 0.01
2016-10-27 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 198765 0.01
2016-10-02 He (Wei-Wu) Director Buy 1871605 1.19
2016-07-19 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 98271 --
2016-07-19 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 66255 --
2016-07-13 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 585790 --
2016-07-13 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 394942 --
2016-06-23 Sparkle Byte Ltd Beneficial Owner of More than 10% Class Buy 3753855 1.19
2016-02-21 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 680113 0.01
2016-02-21 Spectrum Pharmaceuticals Inc Beneficial Owner of More than 10% Class Buy 1008764 0.01
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 300 0.71
2016-01-18 Hu (Cynthia Wong) Chief Operating Officer Buy 11837 0.72
2016-01-18 Hu (Cynthia Wong) Chief Operating Officer Buy 400 0.75
2016-01-18 Hu (Cynthia Wong) Chief Operating Officer Buy 400 0.75
2016-01-18 Hu (Cynthia Wong) Chief Operating Officer Buy 4163 0.72
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 1100 0.74
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 7537 0.73
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 1100 0.74
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 6063 0.72
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 7537 0.73
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 300 0.71
2016-01-18 Ren (Ken K) Chief Executive Officer Buy 6063 0.72

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Teachers Advisors LLC 107422 0.11% -- -- 2019-03-31
State Street Corporation 795175 0.83% 28868 3.77% 2019-03-31
Northern Trust Investments Inc 973110 1.02% 28269 2.99% 2019-07-31
Wellington Shields & Co., LLC 1126650 1.18% 46000 4.26% 2019-03-31
Wellington Shields Capital Mgmt LLC 1145949 1.20% -31182 -2.65% 2019-03-31
Vanguard Investments Australia Ltd 1285278 1.34% -- -- 2019-07-31
BlackRock Fund Advisors 1675884 1.75% 2155 0.13% 2019-07-31
Vanguard Group Inc 2331167 2.44% 116638 5.27% 2019-03-31
BlackRock Inc 2738109 2.86% -98823 -3.48% 2019-03-31
Geode Capital Management, LLC 622336 0.65% -547604 -46.81% 2019-03-31
Northern Trust Corp 600509 0.63% 458 0.08% 2019-03-31
Northern Trust Investments N A 600509 0.63% 458 0.08% 2019-03-31
California Public Employees Retrmnt Sys 139600 0.15% -- -- 2019-03-31
AXA Equitable Funds Management Group, LLC 141827 0.15% -- -- 2019-07-31
BlackRock Institutional Trust Company NA 178940 0.19% -13118 -6.83% 2019-07-31
ALPS Advisors Inc 230154 0.24% 9939 4.51% 2019-03-31
Charles Schwab Investment Management Inc 253751 0.27% -19645 -7.19% 2019-03-31
BlackRock 307971 0.32% -16322 -5.03% 2019-07-31
State Street Global Advisors 429247 0.45% -- -- 2019-07-31
Fidelity Management & Research Company 581643 0.61% 20623 3.68% 2019-07-31
BlackRock Asset Management Canada Ltd 1070775 1.12% -882 -0.08% 2019-05-31
Bank of New York Mellon Corp 172947 0.18% 19781 12.91% 2018-12-31
BNY Mellon Investment Management 139354 0.15% 19596 16.36% 2018-12-31
Deutsche Bank AG 99968 0.11% 18156 22.19% 2018-09-30
TIAA-CREF Investment Management LLC 199536 0.21% 88664 79.97% 2018-09-30
Morgan Stanley & Co Inc 145388 0.16% 51634 55.07% 2018-06-30
Morgan Stanley - Brokerage Accounts 147257 0.16% 51745 54.18% 2018-06-30
Goldman Sachs Group Inc 178063 0.19% 159202 844.08% 2018-03-31
Goldman, Sachs & Co. 178063 0.19% 159202 844.08% 2018-03-31
Royce & Associates, LP 120000 0.13% 120000 -- 2018-06-30
California State Teachers Retirement Sys 76371 0.09% 76371 -- 2018-06-30
Teachers Advisors Inc 95606 0.11% 95606 -- 2018-06-30
Northern Trust Asset Management 121020 0.14% 76 0.06% 2018-07-31
Royce & Associates, LLC 120000 0.14% 120000 -- 2018-06-30
State Street Corp 593163 0.69% 569534 2410.32% 2018-06-30
WEALTH STRATEGY HOLDING Ltd. 6296292 9.24% 6296292 -- 2017-10-23
Spectrum Pharmaceuticals Inc 11547675 13.42% 6142293 113.63% 2018-04-17
T. Rowe Price Associates, Inc. 49733 0.06% 333 0.67% 2018-06-30
AQR Capital Management LLC 76350 0.09% 76350 -- 2018-06-30
Susquehanna Financial Group, LLLP 140680 0.18% 116139 473.24% 2018-03-31
Millennium Management LLC 430297 0.54% 388083 919.32% 2018-03-31
LAURION CAPITAL MANAGEMENT LP 55729 0.07% 55729 -- 2018-03-31
Raymond James Finl Svs Advisors, Inc. 52090 0.07% 32000 159.28% 2018-03-31
BlackRock Advisors (UK) Ltd 46200 0.06% -17679 -27.68% 2018-03-31
Renaissance Technologies Corp 41800 0.05% -108800 -72.24% 2018-03-31
Perceptive Advisors LLC 43682 0.05% -40000 -47.80% 2018-03-31
Susquehanna International Group, LLP 140680 0.18% 116139 473.24% 2018-03-31
Moors & Cabot Inc 24663 0.04% -1390 -5.34% 2017-12-31
ALPINE SECURITIES USVI LLC 27729 0.04% 27729 -- 2017-12-31
Mellon Capital Management Corporation 33402 0.04% 28331 558.69% 2018-03-31
Citadel Advisors Llc 18398 0.03% 18398 -- 2017-12-31
Virtu Financial LLC 40790 0.07% 40790 -- 2017-09-30
ZHEJIANG KANGLAITE GROUP CO Ltd 4938269 8.20% 2880656 140.00% 2016-12-31
Royal Bank Of Canada 17649 0.03% 77 0.44% 2017-12-31
Guggenheim Capital LLC 12242 0.02% 12242 -- 2017-09-30
FMG LLC 5972 0.01% -- -- 2018-01-31
BlackRock Advisors LLC 7740 0.01% -- -- 2018-01-31
Everett Harris & Co 10002 0.02% -- -- 2017-12-31
Manatuck Hill Partners LLC 15090 0.03% -- -- 2017-09-30
Howland Capital Management Inc 24139 0.04% 24139 -- 2017-09-30
USAA Asset Management Company 7740 0.01% -- -- 2017-09-30
Guggenheim Funds Investment Advisors LLC 10883 0.02% -- -- 2017-12-20
Williams Jones & Associates Inc 17812 0.04% -- -- 2016-09-30
He Xie Ai Qi Investment Management (Beijing) Co Ltd 8498765 17.90% -- -- 2016-07-27
Celgene Corporation 2464987 4.00% 3664203 0.10% 1999-11-30
Spectrum Pharmaceuticals, Inc. and affiliated entities 5405382 4.00% 8035100 0.20% 1999-11-30
IDG-Accel China and affiliated entities 6842783 4.00% 10171797 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT R2000 Growth Index Fund - Non-Lending 191434 0.20% -- -- 2019-06-30
EQ/2000 Managed Volatility Portfolio 75132 0.08% -- -- 2019-05-31
Vanguard Total Stock Market Index Fund 1285278 1.34% -- -- 2019-06-30
iShares Russell 2000 ETF 1044775 1.09% 2046 0.20% 2019-07-30
Vanguard Extended Market Index Fund 736255 0.77% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 413202 0.43% -- -- 2019-07-30
State Street Russell Small Cap 203924 0.21% -- -- 2019-06-30
State Street Russell Small/Mid Cap 196821 0.21% -- -- 2019-06-30
NT R2000 Index Fund - NL 192597 0.20% 7631 4.13% 2019-06-30
Schwab US Small-Cap ETF 152690 0.16% 130 0.09% 2019-07-31
BlackRock Extended Equity Market 94103 0.10% -129 -0.14% 2019-06-30
Northern Trust Russell 2000 Index DC NL 146213 0.15% 5176 3.67% 2019-06-30
NT R2000 Growth Index Fund - Lending 135492 0.14% 2172 1.63% 2019-06-30
iShares Micro-Cap ETF 128847 0.13% -- -- 2019-07-30
Schwab Small Cap Index Fund 105221 0.11% -- -- 2019-06-30
Russell 2000 Index Non-Lendable Fund E 97484 0.10% -13117 -11.86% 2019-06-30
Fidelity 79991 0.08% -- -- 2019-06-30
The Vanguard - Russell 2000 Grwth Idx CF 88275 0.09% 14088 18.99% 2019-06-30
BlackRock Russell 2000 81070 0.08% 1333 1.67% 2019-03-31
ALPS Medical Breakthroughs ETF 228062 0.24% -- -- 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 996973 1.04% -1674 -0.17% 2019-05-30
AXA 2000 Managed Volatility Portfolio 75132 0.08% -- -- 2019-01-31
TIAA-CREF Small-Cap Blend 73710 0.08% -- -- 2019-01-31
iShares Russell 2000 Small-Cap Index Fd 60139 0.06% -- -- 2019-02-28
CREF Stock Account 65481 0.07% 1275 1.99% 2019-01-31
AQR Small Cap Momentum Style Fund 65581 0.07% -10573 -13.88% 2018-12-31
Vanguard Russell 2000 Index Fund 58961 0.06% -900 -1.50% 2019-01-31
LVIP SSgA Small Cap Index Fund 50700 0.05% -- -- 2018-12-31
iShares Russell 2000 Value ETF 49946 0.05% -- -- 2019-01-31
Vanguard Balanced Index Fund 49361 0.05% -- -- 2019-01-31
Vanguard Instl Total Stock Market Idx Fd 47384 0.05% -- -- 2019-01-31
Master Small Cap Index Series 60139 0.06% -- -- 2018-12-31
Royce Smaller-Companies Growth Fund 78742 0.08% -41258 -34.38% 2018-09-30
Fidelity Spartan 84183 0.10% -- -- 2018-07-31
The Vanguard Russell 2000 Growth Index 82729 0.10% 2810 3.52% 2018-07-31
BlackRock Russell 2500 67563 0.08% 67563 -- 2018-06-30
AXA 2000 Managed Volatility K 75132 0.09% 2984 4.14% 2018-07-31
AQR Small Cap Momentum Style I 65365 0.08% 65365 -- 2018-06-30
CREF Stock R1 73173 0.08% -3862 -5.01% 2018-07-31
TIAA-CREF Small-Cap Blend Idx Inst 60885 0.07% -- -- 2018-07-31
Vanguard Russell 2000 ETF 56508 0.07% 1050 1.89% 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 55922 0.06% -- -- 2018-07-31
Schwab Small Cap Index 93000 0.11% -- -- 2018-07-31
BlackRock Extended Equity Market K 93463 0.11% 2541 2.79% 2018-06-30
Vanguard Total Stock Mkt Idx 874637 1.01% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 604372 0.70% 2624 0.44% 2018-07-31
iShares Russell 2000 Growth 441117 0.46% -425 -0.10% 2018-09-12
Royce Smaller-Companies Growth Svc 120000 0.14% 120000 -- 2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 121020 0.14% 76 0.06% 2018-07-31
iShares Micro-Cap 133898 0.14% -- -- 2018-09-12
LVIP SSgA Small Cap Index Std 44500 0.05% 44500 -- 2018-06-30
iShares Russell 2000 Value 49946 0.06% -- -- 2018-08-01
Master Small Cap Index 35272 0.04% 35272 -- 2018-06-30
BNY Mellon EB DL Small Cap SIF 34645 0.04% 34645 -- 2018-06-30
Vanguard Russell 2000 Growth ETF 32411 0.04% 32411 -- 2018-06-30
Vanguard Balanced Index Inv 31240 0.04% 10800 52.84% 2018-06-30
BlackRock Russell 3000 15101 0.02% 15101 -- 2018-06-30
iShares Russell 3000 16756 0.02% -- -- 2018-07-12
Pacific Select Small-Cap Index I 18950 0.02% 18950 -- 2018-06-30
Northern Small Cap Index 29323 0.03% 29323 -- 2018-06-30
iShares Core S&P Total US Stock Mkt 13795 0.02% 6 0.04% 2018-07-05
BNY Mellon EB DL Mkt Completion 25269 0.03% 22142 708.09% 2018-03-31
T. Rowe Price Extended Equity Market Idx 24500 0.03% -- -- 2018-03-31
SPDR 10536 0.01% 266 2.59% 2018-07-03
Wilshire Micro-Cap ETF 12195 0.01% -- -- 2018-07-03
The Vanguard Total Stock Market Index 9042 0.01% 2400 36.13% 2018-05-31
Schwab Total Stock Market Index 10961 0.01% 10961 -- 2018-05-31
BNY Mellon Market Completion Fund UC1 8133 0.01% 6189 318.36% 2018-03-31
AXA/Lord Abbett Micro Cap K 5972 0.01% -- -- 2018-04-30
USAA Extended Market Index 7740 0.01% -- -- 2018-04-30
BlackRock U.S. Equity Market F 6974 0.01% 739 11.85% 2018-03-31
JHVIT Total Stock Market Index I 2445 -- -- -- 2018-04-30
SSgA U.S. Total Market Index Fd Class I 1033 -- -67 -6.09% 2017-12-31
Master Extended Market Index Series 7740 0.01% -- -- 2018-01-31
BlackRock LifePath 19 -- 7 58.33% 2016-03-31
BlackRock Extended Equity Market Fund 15681 -- -32 -0.20% 2015-09-30
Vanguard US Equity Index 13382 -- -- -- 2015-07-31
The Vanguard - Total Stk Mkt Idx Trust. CF 8174 -- -- -- 2015-10-31
Mellon Capital EB DL Mkt Completion Fund 3967 -- -- -- 2015-09-30
AXA/Lord Abbett Micro Cap Portfolio 2802 -- -- -- 2015-09-30
BlackRock U.S. Equity Market Fund 2651 -- -15 -0.60% 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 899 -- -- -- 2015-09-30
Fidelity Spartan® Total Market Idx Fund 289 -- -- -- 2015-09-30
Vanguard Instl Total Stock Market Index 200 -- -22362 -99.10% 2015-10-31
Fidelity Spartan® Extended Mkt Indx Fd 37512 0.10% -- -- 2015-09-30
BlackRock LifePath® Index 2060 Fund 6 -- 6 -- 2015-06-30

Cynthia Wong Hu Founder of Women in Bio, Inc., Cynthia Wong Hu currently is COO, Secretary, Vice President & General Counsel at CASI Pharmaceuticals, Inc. In the past Dr. Hu occupied the position of Attorney at Klehr, Harrison, Harvey, Branzburg & Ellers LLP, Attorney at Littman Krooks LLP, Counsel at Voya Insurance & Annuity Co., Senior Attorney at Powell Goldstein LLP and Director at Women in Bio, Inc. She received a graduate degree from Rutgers State University of New Jersey and an undergraduate degree from New York University.
Ken Keyong Ren Ken Keyong Ren is an entrepreneur and businessperson who founded ImmunoVentis, Inc., China Innovation Center for Life Science, Novemed, Inc. and AHT, Inc. and who has been the head of 5 different companies. Dr. Ren is on the board of CASI Pharmaceuticals, Inc. (former Chief Executive Officer & Director). In his past career he held the position of Chief Executive Officer for ImmunoVentis, Inc., Chief Executive Officer at China Innovation Center for Life Science, Chief Executive Officer for Novemed, Inc., Chief Investment Director at CCBI Healthcare Fund, Research Scientist at Pfizer Inc. and President of Accelovance China. He received a doctorate from State University of New York at Buffalo and a doctorate from Shandong Medical University.
Franklin Cary Salisbury Franklin Cary Salisbury is on the board of CASI Pharmaceuticals, Inc. and National Foundation for Cancer Research (former President). Mr. Salisbury received an undergraduate degree from Yale University, a graduate degree from The University of Chicago, a graduate degree from Yale Divinity School and a graduate degree from the University of Georgia School of Law.
Rajesh C. Shrotriya Rajesh C. Shrotriya is on the board of CASI Pharmaceuticals, Inc. and 6 other companies. In the past he was Chairman & Chief Executive Officer at Spectrum Pharmaceuticals, Inc., Executive Director-Worldwide CNS Clinical Research at Bristol-Myers Squibb Co., Chief Scientific Officer & Executive VP at SuperGen, Inc. and Chief Medical Officer & VP-Medical Affairs at MGI PHARMA, Inc. Dr. Shrotriya received an undergraduate degree from Armed Forces Medical College, an undergraduate degree from Dr. Bhim Rao Ambedkar University and a doctorate from The Grant Government Medical College.
Wei-Wu He Founder of OriGene Technologies, Inc., Emerging Technology Partners LLC and Intradigm Corp., Wei-Wu He is an entrepreneur and businessperson who has been at the helm of 6 different companies and presently occupies the position of Chairman of OriGene Technologies, Inc., Chairman at Beijing Genetron Health Gene Technology Co. Ltd., Chairman of Beijing Genetron Biotechnology Co. Ltd., Executive Chairman & Chief Executive Officer of CASI Pharmaceuticals, Inc. and General Partner at Emerging Technology Partners LLC. Wei-Wu He is also on the board of Intradigm Corp., MithraGen, Inc. and Human Longevity, Inc. Dr. He previously was Chairman & Chief Executive Officer of Cytomyx Holdings Plc and President of Human Genome Sciences, Inc. Dr. He received a doctorate from Baylor College of Medicine and an MBA from The Wharton School of the University of Pennsylvania.
Zuie Chin Huang Zuie Chin Huang is a businessperson who has been at the helm of 6 different companies. Currently, he occupies the position of Chairman for XW Laboratories, Inc., Co-Chairman at JHL Biotech, Inc., Chairman for Wuhan Kindstar Co. Ltd., Chairman at Windtree Therapeutics, Inc. and Vice President-Corporate Development for OriGene Technologies, Inc. Mr. Huang is also Managing Partner at Kleiner Perkins Caufield & Byers China and General Partner for KPCB China Fund II LP and on the board of 7 other companies. He previously occupied the position of President of Anesiva, Inc., Partner at Panacea Venture, Venture Partner at Vivo Capital LLC, Principal at Bristol-Myers Squibb Co., Principal at Tularik, Inc., Principal at GlaxoSmithKline LLC and Project Manager at ALZA Corp. Zuie Chin Huang received an undergraduate degree from the University of California, Berkeley and an MBA from Stanford Graduate School of Business.
Cynthia Wong Hu Founder of Women in Bio, Inc., Cynthia Wong Hu currently is COO, Secretary, Vice President & General Counsel at CASI Pharmaceuticals, Inc. In the past Dr. Hu occupied the position of Attorney at Klehr, Harrison, Harvey, Branzburg & Ellers LLP, Attorney at Littman Krooks LLP, Counsel at Voya Insurance & Annuity Co., Senior Attorney at Powell Goldstein LLP and Director at Women in Bio, Inc. She received a graduate degree from Rutgers State University of New Jersey and an undergraduate degree from New York University.
Quan Zhou Quan Zhou holds the position of General Partner & Managing Director at IDG Capital Partners Co., Ltd. Dr. Zhou is also Managing Member at IDG Technology Venture Investment IV LLC, Managing Member at IDG Technology Venture Investments LP and Managing Member at IDG Technology Venture Investment III LLC and on the board of 8 other companies. In the past he was President at IDG Technology Venture Investment, Inc. Quan Zhou received a graduate degree from Chinese Academy of Sciences, an undergraduate degree from the University of Science & Technology of China and a doctorate from Rutgers State University of New Jersey.
Yue Wu Founder of Crown Bioscience International, Unimicro Technologies, Inc. and Crown Bioscience, Inc., Yue Wu is an entrepreneur is on the board of CASI Pharmaceuticals, Inc., SCILEX Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc. He previously occupied the position of Chief Operating Officer for Unimicro Technologies, Inc., Chief Business Officer for Starvax, Inc., Head-Asian Operations at Burrill & Co. LLC, Chief Business Officer of Starvax International, Inc. (China), President, CEO & Chief Scientific Officer at Crown Bioscience, Inc., President, Chief Executive & Scientific Officer at Crown Bioscience International and Manager-Business Development & Strategic Planning at F. Hoffmann-La Roche Ltd. He received an undergraduate degree from Fudan University, a doctorate and an MBA from the University of California, Berkeley and a graduate degree from the University of Illinois.
James E. Goldschmidt James E. Goldschmidt is President-United States at Sandoz, Inc. and Senior Vice President-Business Development for CASI Pharmaceuticals, Inc. In his past career he occupied the position of Vice President-Business & Commercial Development at TetraLogic Pharmaceuticals Corp., Vice President-Business Development of ImmuneXcite, Inc., Product Director at GlaxoSmithKline Plc, Executive Director-Business Development at Johnson & Johnson, Chief Operating Officer for Macrophage Therapeutics, Inc. and Executive Director-Oncology New Business at Wyeth Pharmaceuticals LLC. Dr. Goldschmidt received an undergraduate degree from Villanova University, a graduate degree from Drexel University and a doctorate from Temple University School of Medicine.
Alexander A. Zukiwski Alexander A. Zukiwski holds the position of Chief Medical Officer of CASI Pharmaceuticals, Inc. In his past career he was President, CEO, Director & Chief Medical Officer at Arno Therapeutics, Inc., Principal at Johnson & Johnson and Chief Medical Officer & SVP-Clinical Research at MedImmune LLC. He received an undergraduate degree from the University of Alberta and a doctorate from the University of Calgary.
George Chi Presently, George Chi occupies the position of Chief Financial & Accounting Officer at CASI Pharmaceuticals, Inc. In his past career he occupied the position of Chief Financial Officer for Bpl Plasma, Inc. and Vice President-Finance for Flavors Holdings, Inc. He received an undergraduate degree from Tsinghua University and an MBA from Yale School of Management.
Wei Zhang Wei Zhang is President-CASI China at CASI Pharmaceuticals, Inc. In the past Mr. Zhang was Chief Executive Officer of Sandoz China Pharmaceutical Co. Ltd. and President for Casi Beijing Pharmaceuticals Co. Ltd. Mr. Zhang received an undergraduate degree and a graduate degree from the University of Science & Technology of China and an MBA from the University of California, Los Angeles.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐